

# Maite Solas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1278543/publications.pdf>

Version: 2024-02-01

38  
papers

2,447  
citations

304743

22  
h-index

315739

38  
g-index

43  
all docs

43  
docs citations

43  
times ranked

4788  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dysbiosis and Alzheimer's Disease: Cause or Treatment Opportunity?. Cellular and Molecular Neurobiology, 2022, 42, 377-387.	3.3	24
2	Brain Metabolic Alterations in Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 3785.	4.1	28
3	Trimethylamine N-oxide (TMAO) drives insulin resistance and cognitive deficiencies in a senescence accelerated mouse model. Mechanisms of Ageing and Development, 2022, 204, 111668.	4.6	16
4	Expression of Endothelial NOX5 Alters the Integrity of the Blood-Brain Barrier and Causes Loss of Memory in Aging Mice. Antioxidants, 2021, 10, 1311.	5.1	11
5	5-HT7 receptors in Alzheimer's disease. Neurochemistry International, 2021, 150, 105185.	3.8	12
6	Biomarkers in Alzheimer's disease. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 27-37.	0.2	13
7	Astrocytic GLUT1 ablation improves systemic glucose metabolism and promotes cognition. Alzheimer's and Dementia, 2021, 17, e058650.	0.8	2
8	GLUT12 Expression in Brain of Mouse Models of Alzheimer's Disease. Molecular Neurobiology, 2020, 57, 798-805.	4.0	14
9	Reduced Adrenomedullin Parallels Microtubule Dismantlement in Frontotemporal Lobar Degeneration. Molecular Neurobiology, 2018, 55, 9328-9333.	4.0	1
10	Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice. International Journal of Pharmaceutics, 2018, 543, 245-256.	5.2	11
11	Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. Nutrients, 2018, 10, 1398.	4.1	403
12	Interactions Between Age, Diet, and Insulin and Their Effect on Cognition. , 2018, , 223-238.		0
13	Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 5177-5183.	4.0	21
14	Serotonin 5-HT6 Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status. CNS Drugs, 2017, 31, 19-32.	5.9	82
15	Inflammation and gut-brain axis link obesity to cognitive dysfunction: plausible pharmacological interventions. Current Opinion in Pharmacology, 2017, 37, 87-92.	3.5	119
16	Exploring Pharmacological Mechanisms of Lavender (Lavandula angustifolia) Essential Oil on Central Nervous System Targets. Frontiers in Pharmacology, 2017, 8, 280.	3.5	169
17	Downregulation of glutamatergic terminals (VGLUT1) driven by A $\beta$ in Alzheimer's disease. Hippocampus, 2016, 26, 1303-1312.	1.9	32
18	JNK: A Putative Link Between Insulin Signaling and VGLUT1 in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 50, 963-967.	2.6	3

#	ARTICLE	IF	CITATIONS
19	Precision Obesity Treatments Including Pharmacogenetic and Nutrigenetic Approaches. Trends in Pharmacological Sciences, 2016, 37, 575-593.	8.7	36
20	Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity. Cell, 2016, 165, 882-895.	28.9	167
21	Lipoic acid improves neuronal insulin signalling and rescues cognitive function regulating VGlut1 expression in high-fat-fed rats: Implications for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 511-517.	3.8	20
22	Resistin, an Adipokine with Non-Generalized Actions on Sympathetic Nerve Activity. Frontiers in Physiology, 2015, 6, 321.	2.8	28
23	Venlafaxine reverses decreased proliferation in the subventricular zone in a rat model of early life stress. Behavioural Brain Research, 2015, 292, 79-82.	2.2	4
24	c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer's Disease. Frontiers in Pharmacology, 2015, 6, 321.	3.5	284
25	Treatment Options in Alzheimer's Disease: The GABA Story. Current Pharmaceutical Design, 2015, 21, 4960-4971.	1.9	103
26	The paradox of neuronal insulin action and resistance in the development of aging-associated diseases. Alzheimer's and Dementia, 2014, 10, S3-11.	0.8	66
27	CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiology of Aging, 2013, 34, 805-808.	3.1	152
28	Stress contributes to the development of central insulin resistance during aging: Implications for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2332-2339.	3.8	35
29	Mineralocorticoid Receptor Activation Induces Insulin Resistance Through c-Jun N-terminal kinases in Response to Chronic Corticosterone: Cognitive Implications. Journal of Neuroendocrinology, 2013, 25, 350-356.	2.6	23
30	Mechanisms Involved in BACE Upregulation Associated to Stress. Current Alzheimer Research, 2012, 9, 822-829.	1.4	13
31	Long lasting effects of early-life stress on glutamatergic/GABAergic circuitry in the rat hippocampus. Neuropharmacology, 2012, 62, 1944-1953.	4.1	103
32	Stress-induced anhedonia is associated with an increase in Alzheimer's disease-related markers. British Journal of Pharmacology, 2012, 165, 897-907.	5.4	54
33	Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation. Hippocampus, 2011, 21, 999-1009.	1.9	46
34	Insulin Levels are Decreased in the Cerebrospinal Fluid of Women with Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 405-413.	2.6	68
35	Interactions Between Age, Stress and Insulin on Cognition: Implications for Alzheimer's Disease. Neuropsychopharmacology, 2010, 35, 1664-1673.	5.4	109
36	HPA Axis Dysregulation Associated to Apolipoprotein E4 Genotype in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 829-838.	2.6	73

#	ARTICLE	IF	CITATIONS
37	Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects. International Journal of Neuropsychopharmacology, 2010, 13, 775-784.	2.1	26
38	Altered NCAM Expression Associated with the Cholinergic System in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 659-668.	2.6	38